CTOs on the Move

Enveda Biosciences

www.envedabio.com

 
At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses nature`s complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.envedabio.com
  • 1880 S Flatiron Court Suite K
    Boulder, CO USA 80301
  • Phone: 720.390.5994

Executives

Name Title Contact Details

Similar Companies

AltMed

AltMed LLC is a fully integrated, science-based Florida company bringing compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabis.

Novascreen Biosciences Corporation

Novascreen Biosciences Corporation is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tectonic Therapeutic

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.

Tarveda Therapeutics

Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.

Xontogeny

Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease.